However, the immune-reactivity score for mTOR was higher in the tumor center of patients with evidence of distant metastases (p = 0.01), and MMP7 was more highly expressed in the tumors of patients with nodal involvement (tumor center: p = 0.01, invasive front: p = 0.019; data not shown). This evidence concerns the gene MMP7 and neoplasm.